Abstract

Introduction: Second-generation antipsychotics (SGAs), clozapine, risperidone, olanzapine, quetiapine, aripiprazole, ziprasidone, indicated for the treatment of schizophrenia and some of these for the treatment of bipolar disorder, are metabolized in the liver by the cytochrome P450 (CYP) system, a superfamily of isoenzymes. CYP450 enzyme activity is different among people. Different groups are classified as poor metabolizers (PMs), intermediate metabolizers (IMs), extensive metabolizers (EMs), ultra rapid metabolizers (UMs) [1]. Drug interaction with other psychotropic (selective serotonin reuptake inhibitors, mood stabilizers) or somatic (antibiotics, beta-blockers) medication, trough inhibition or induction of CYP450 activity, also affect SGAs metabolism speed, plasma levels, therapeutic effect and toxicity [2]. In clinical practice Therapeutic Drug Monitoring (TDM) is an established procedure for lithium, carbamazepine and valproate treatment. TDM is suggested during SGAs treatment if there is lack of clinical response or a suspect of poor compliance or toxic events at therapeutic doses, or side effects with subtherapeutic doses, drug-drug interactions, liver impairment, suspect of CYP450 polymorphism (PMs or UMs) or in elderly patients [3–5]. Materials and Methods: In the Mental Health Service of ASL Biella TDM has been carried out in collaboration with pharmaco-toxicological analysis laboratories of the universities of Bologna, Messina and Milan. Results: In 15 patients in drug treatment with SGAs, TDM was carried out to prevent toxic events of augmentation, when antidepressant (SSRI) are coadministrated, in some cases [6]. To understand the lack of clinical outcome in other cases [7]; in three cases TDM showed a clear non compliance of the patients to drug treatment; in one case TDM showed a very high plasma level of SGA and permitted a early discontinuation of SSRI, to avoid serious toxic events to the patient [8]. In eleven cases TDM showed a good compliance of patients to drug treatment and no risk of toxic events. Conclusion: Safety and efficacy are two key elements in clinical practice and TDM may contribute to both. TDM might become a helpful tool in a modern approach to drug therapy in psychiatry and guidelines to optimise its use [4,9] are welcome.

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.